Several other monotherapy immune checkpoint inhibitors targeting the PD-1/PD-L1 axis, including atezolizumab (NCT04157985), durvalumab (NCT03847428), toripalimab (NCT03949231), and tislelizumab (NCT03412773), also showed an immune response against liver cancer [10,44–48]. The gene discussed is CD274; the disease is liver cancer.